Jeffrey E Gotts

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5396465/publications.pdf

Version: 2024-02-01

25 papers	3,142 citations	516710 16 h-index	580821 25 g-index
25 all docs	25 docs citations	25 times ranked	5403 citing authors

#	Article	IF	Citations
1	Sepsis: pathophysiology and clinical management. BMJ, The, 2016, 353, i1585.	6.0	653
2	Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury. Nature, 2015, 517, 621-625.	27.8	562
3	Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respiratory Medicine,the, 2019, 7, 154-162.	10.7	443
4	What are the respiratory effects of e-cigarettes?. BMJ, The, 2019, 366, l5275.	6.0	309
5	Treatment for severe acute respiratory distress syndrome from COVID-19. Lancet Respiratory Medicine,the, 2020, 8, 433-434.	10.7	254
6	Pulmonary toxicity of e-cigarettes. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L193-L206.	2.9	225
7	Local lung hypoxia determines epithelial fate decisions during alveolar regeneration. Nature Cell Biology, 2017, 19, 904-914.	10.3	202
8	Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 307, L395-L406.	2.9	84
9	Mesenchymal Stem Cells and Acute Lung Injury. Critical Care Clinics, 2011, 27, 719-733.	2.6	80
10	Persistent Pathology in Influenza-Infected Mouse Lungs. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 613-615.	2.9	63
11	Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Annals of Intensive Care, 2014, 4, 22.	4.6	53
12	Assessment of industry data on pulmonary and immunosuppressive effects of IQOS. Tobacco Control, 2018, 27, s20-s25.	3.2	50
13	Possible hepatotoxicity of IQOS. Tobacco Control, 2018, 27, s39-s40.	3.2	37
14	Cigarette Smoke Exposure Worsens Endotoxin-Induced Lung Injury and Pulmonary Edema in Mice. Nicotine and Tobacco Research, 2017, 19, 1033-1039.	2.6	26
15	Clinically relevant model of pneumococcal pneumonia, ARDS, and nonpulmonary organ dysfunction in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L717-L736.	2.9	24
16	Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L25-L40.	2.9	20
17	Treating ARDS: new hope for a tough problem. Lancet Respiratory Medicine,the, 2014, 2, 84-85.	10.7	13
18	Cathepsin L Helps to Defend Mice from Infection with Influenza A. PLoS ONE, 2016, 11, e0164501.	2.5	9

#	Article	IF	Citations
19	The ex vivo perfused human lung is resistant to injury by high-dose S. pneumoniae bacteremia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L218-L227.	2.9	8
20	Endogenous and Exogenous Cell-Based Pathways for Recovery from Acute Respiratory Distress Syndrome. Clinics in Chest Medicine, 2014, 35, 797-809.	2.1	7
21	High-power vaping injures the human lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L703-L704.	2.9	7
22	Reply to â€œLetter to the Editor: Pulmonary toxicity of electronic cigarettes: more doubts than certaintiesâ€• American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L966-L967.	2.9	5
23	Cell Therapy for Lung Disease. Chest, 2013, 143, 1525-1527.	0.8	4
24	Precision medicine for cell therapy in acute respiratory distress syndrome â€“ Authors' reply. Lancet Respiratory Medicine,the, 2019, 7, e14.	10.7	2
25	Delayed angiopoietinâ€2 blockade reduces influenzaâ€induced lung injury and improves survival in mice. Physiological Reports, 2021, 9, e15081.	1.7	2